Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
ALXO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.68 - $17.83
Previous CloseN/A
Volume579.15K
Average Volume (3M)1.06M
Market Cap
$38.29M
Enterprise Value-$35.31M
Total Cash (Recent Filing)$17.57M
Total Debt (Recent Filing)$9.90M
Price to Earnings (P/E)―
Beta2.36
Next Earnings
May 08, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding53,384,144
10 Day Avg. Volume549,722
30 Day Avg. Volume1,055,584
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.27
Forecast
1Y Price Target
$4.63Price Target Upside580.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Market PotentialEvorpacept's commercial potential across multiple indications suggests a strong future market presence.
Research And DevelopmentAnnounced new trials with Evorpacept for breast and colorectal cancer, highlighting ongoing research and development efforts.
Bears Say
Clinical DataFull Phase II data in gastric failed to meet expectations and the efficacy had come way down in H2 of the study post interim.
Financial SustainabilityALX Oncology has approximately 1.3 years of cash left, which may raise concerns about the company's financial sustainability.
Investor SentimentShort interest in the stock is relatively high, indicating some investor skepticism.
---
Ownership Overview
3.43% Insiders
10.12% Mutual Funds
38.81% Other Institutional Investors
41.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALXO FAQ
What was ALX Oncology Holdings’s price range in the past 12 months?
ALX Oncology Holdings lowest stock price was $0.68 and its highest was $17.82 in the past 12 months.
What is ALX Oncology Holdings’s market cap?
ALX Oncology Holdings’s market cap is $38.29M.
When is ALX Oncology Holdings’s upcoming earnings report date?
ALX Oncology Holdings’s upcoming earnings report date is May 08, 2025 which is in 41 days.
How were ALX Oncology Holdings’s earnings last quarter?
ALX Oncology Holdings released its earnings results on Mar 06, 2025. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.67 by $0.12.
Is ALX Oncology Holdings overvalued?
According to Wall Street analysts ALX Oncology Holdings’s price is currently Undervalued.
Does ALX Oncology Holdings pay dividends?
ALX Oncology Holdings does not currently pay dividends.
What is ALX Oncology Holdings’s EPS estimate?
ALX Oncology Holdings’s EPS estimate is -0.51.
How many shares outstanding does ALX Oncology Holdings have?
ALX Oncology Holdings has 53,384,144 shares outstanding.
What happened to ALX Oncology Holdings’s price movement after its last earnings report?
ALX Oncology Holdings reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.67. Following the earnings report the stock price went down -19.084%.
Which hedge fund is a major shareholder of ALX Oncology Holdings?
Currently, no hedge funds are holding shares in ALXO
---
ALX Oncology Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.63 (580.88% Upside)
$4.63 (580.88% Upside)
Blogger Sentiment
Bullish
ALXO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 96.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $25.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.93%
12-Months-Change
Fundamentals
Return on Equity
-88.91%
Trailing 12-Months
Asset Growth
-39.08%
Trailing 12-Months
Company Description
ALX Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
---
ALXO Stock 12 Month Forecast
Average Price Target
$4.63
▲(580.88% Upside)
Technical Analysis
Fate Therapeutics
―
Karyopharm Therapeutics
―
Affimed
―
Adaptimmune Therapeutics
―
IGM Biosciences
―
Best Analysts Covering ALXO
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-34.14%
reiterated a buy rating 21 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -34.14% per trade.
---